An independent two-stage DCF analysis by a frontier AI model.
Quest Diagnostics operates as a fundamental pillar of the U.S. healthcare system. Along with LabCorp, it commands a formidable duopoly in the independent clinical laboratory space. Its primary competitive advantage is scale: massive, automated testing facilities and dense logistical networks allow Quest to perform routine tests at a fraction of the cost of hospital-based labs.
While pricing pressures from Medicare and private insurers present a perpetual headwind, Quest counters this through sheer volume and an aggressive strategy of acquiring hospital outreach labs. It is a slow-growth, defensive business that reliably generates over $1 billion in free cash flow annually, making it a stable asset trading near its fair intrinsic value.
A modest 4% growth rate reflects the mature nature of the clinical lab industry, offset by continuous reimbursement pressures, with growth relying heavily on tuck-in acquisitions.
A lower 7.5% discount rate is appropriate given Quest's highly predictable, recession-resistant cash flows and defensive business model.
A 2.0% terminal growth rate aligns with long-term inflation and population growth, reflecting a steady but slow-growth mature market.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $226.36 | $185.20 | $156.71 | $135.81 | $119.84 |
| 1.5% | $254.65 | $203.72 | $169.77 | $145.51 | $127.32 |
| 2.0% | $291.03 | $226.36 | $185.20 | $156.71 | $135.81 |
| 2.5% | $339.53 | $254.65 | $203.72 | $169.77 | $145.51 |
| 3.0% | $407.44 | $291.03 | $226.36 | $185.20 | $156.71 |
■ Undervalued vs current price ■ Overvalued vs current price
The core routine testing market is mature and faces constant reimbursement cuts. Growth must be manufactured through market share gains and acquisitions rather than organic volume explosions.
Quest provides essential healthcare services, making its cash flows highly resilient even during economic downturns, which lowers its overall risk profile.
Cost advantage derived from immense scale. Its centralized labs and dense courier networks result in the lowest per-unit cost for diagnostic testing in the industry.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.